Analytical Data
-
基因名
HER2/CD340
-
简介
The HER2/CD340 Protein is a member of the receptor tyrosine kinase family. HER2/CD340 Protein participates in the PI3K/Akt signaling pathway to regulate the differentiation and apoptosis of neural stem cells in the cochlear nucleus. HER2/CD340 Protein is an overexpressed oncogenic factor in bladder cancer that activates the oncogenic signaling pathway, thereby promoting tumor cell survival/proliferation. HER2/CD340 Protein, Canine (HEK293, His) is the recombinant canine-derived HER2/CD340 protein, expressed by HEK293 , with C-His labeled tag.
- Application
-
生物活性
Measured by its ability to block anti-ErbB2 mediated inhibition of SK-BR-3 human breast cancer cell proliferation. The ED50 this effect is 0.4594 μg/mL in the presence of 0.6 µg/mL Trastuzmab, corresponding to a specific activity is 2.177×103 units/mg. Measured by its ability to block anti-ErbB2 mediated inhibition of SK-BR-3 human breast cancer cell proliferation. The ED50 this effect is 0.4594 μg/mL in the presence of 0.6 µg/mL Trastuzmab, corresponding to a specific activity is 2.177×103 units/mg.
-
别名
Receptor tyrosine-protein kinase erbB-2; MLN 19; CD340; ERBB2; HER2; NEU; NGL
-
种属
Canine
-
表达系统
HEK293
-
标签
C-His
-
纯度
Greater than 95% as determined by reducing SDS-PAGE.
-
蛋白编号
A0A8I3NJW9
-
表达区间
T23-T652
-
氨基酸序列
TQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNLELTYLPANASLSFLQDIQEVQGYVLIAHSQVRQIPLQRLRIVRGTQLFEDNYALAVLDNGDPLEGGIPAPGAAPGGLRELQLRSLTEILKGGVLIQRSPQLCHQDTILWKDVFHKNNQLALTLIDTNRSRACPPCSPACKDAHCWGASSGDCQSLTRTVCAGGCARCKGPQPTDCCHEQCAAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTSCPYNYLSTDVGSCTLVCPLNNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSANIQEFAGCKKIFGSLAFLPESFEGDPASNTAPLQPEQLRVFEALEEITGYLYISAWPDSLPNLSVFQNLRVIRGRVLHDGAYSLTLQGLGISWLGLRSLRELGSGLALIHRNARLCFVHTVPWDQLFRNPHQALLHSANRPEEECVGEGLACYPLCAHGHCWGPGPTQCVNCSQFLRGQECVEECRVLQGLPREYVKDRYCLPCHSECQPQNGSVTCFGSEADQCVACAHYKDPPFCVARCPSGVKPDLSFMPIWKFADEEGTCQPCPINCTHSCADLDEKGCPAEQRASPVT
-
蛋白长度
Partial
-
分子量
75- 95 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HER2, also known as CD340, is a transmembrane receptor tyrosine kinase that is overexpressed in certain types of cancers, particularly breast cancer, and plays a crucial role in tumorigenesis and cancer progression. The HER2 protein is implicated in cell signaling pathways that promote proliferation, survival, and migration of cancer cells. The discovery of HER2's involvement in cancer led to the development of targeted therapy, such as trastuzumab, which demonstrates significant clinical efficacy in HER2-positive breast cancer patients. However, resistance to this therapy remains a significant challenge, necessitating further exploration of HER2 biology and treatment strategies. Recombinant HER2/CD340 proteins are being studied as potential tools for therapeutic intervention and diagnostic applications. By producing these proteins in a controlled manner, researchers can investigate the molecular mechanisms underlying HER2 signaling and explore novel approaches for overcoming therapeutic resistance. Additionally, recombinant HER2 proteins are utilized in developing vaccines and other immunotherapies that aim to elicit a stronger immune response against HER2-expressing tumors. The ongoing research into HER2/CD340 recombinant proteins not only enhances our understanding of this critical receptor but also contributes to the development of innovative strategies to improve treatment outcomes for cancer patients, marking a significant advancement in precision medicine.
